Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 6Recruiting 4Unknown 3Terminated 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 474Carcinoma, Non-Small-Cell Lung 449Breast Neoplasms 331Neoplasm Metastasis 243Colorectal Neoplasms 214Melanoma 213Leukemia, Myeloid, Acute 191Multiple Myeloma 180Recurrence 169Ovarian Neoplasms 169Prostatic Neoplasms 163Lymphoma, Non-Hodgkin 149Lung Neoplasms 134Pancreatic Neoplasms 125Lymphoma 124Carcinoma, Renal Cell 112Leukemia, Lymphocytic, Chronic, B-Cell 111Squamous Cell Carcinoma of Head and Neck 110Stomach Neoplasms 92Carcinoma, Hepatocellular 89Lymphoma, Large B-Cell, Diffuse 88Leukemia 88Triple Negative Breast Neoplasms 86Lymphoma, Follicular 82Head and Neck Neoplasms 79Glioblastoma 75Myelodysplastic Syndromes 70Urinary Bladder Neoplasms 68Small Cell Lung Carcinoma 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 55

Interventions

camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Advanced Tumors × Clear all
NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
12 enrolled

Advanced Tumors

NCT05068856 2024-07-18

A Study of HRS2543 in Patients With Advanced Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 1 Terminated
10 enrolled

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡